|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
1977
|
|
gptkbp:ATCCode
|
gptkb:L02BA01
|
|
gptkbp:availableOn
|
many countries worldwide
|
|
gptkbp:brand
|
gptkb:Nolvadex
gptkb:Soltamox
|
|
gptkbp:CASNumber
|
gptkb:10540-29-1
|
|
gptkbp:contraindication
|
pregnancy
history of blood clots
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
selective estrogen receptor modulator
|
|
gptkbp:eliminationHalfLife
|
5-7 days
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:tamoxifen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nolvadex
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:SSRIs
CYP2D6 inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
estrogen receptor antagonist in breast tissue
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
increased risk of blood clots
hot flashes
|
|
gptkbp:usedFor
|
gptkb:cancer
breast cancer prevention
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zeneca
gptkb:tamoxifen
|
|
gptkbp:bfsLayer
|
6
|